Translational studies on PYY as a novel target in obesity

Current Opinion in Pharmacology

Volumn 11, Issue 6, 2011, Pages 582-585

  Zac Varghese, Sagen ^a   De Silva, Akila ^a   Bloom, Stephen R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; DRUG VEHICLE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; LEPTIN; MK 0557; OBINEPITIDE; OXYNTOMODULIN; PEPTIDE YY; PEPTIDE YY [3-36]; PLACEBO; SODIUM N CAPRYLATE; UNCLASSIFIED DRUG; VELNEPERIT;

ABDOMINAL DISCOMFORT; ARTICLE; CALORIC INTAKE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; HUMAN; INTESTINE ABSORPTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROMODULATION; OBESITY; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY MECHANISM; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 82255192371     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.10.001     Document Type: Review

References (33)

1. World Health Organization Overweight and Obesity Fact Sheet No. 311; 2011.
2. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. National Institutes of Health Obes Res 6 Suppl. 2 1998 51S 209S
3. I. Shai, D. Schwarzfuchs, Y. Henkin, D.R. Shahar, S. Witkow, I. Greenberg, R. Golan, D. Fraser, A. Bolotin, and H. Vardi Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet N Engl J Med 359 2008 229 241 (Pubitemid 352008438)
4. J.S. Torgerson, J. Hauptman, M.N. Boldrin, and L. Sjostrom XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 27 2004 155 161 (Pubitemid 38196725)
5. E.J. DeMaria Bariatric surgery for morbid obesity N Engl J Med 356 2007 2176 2183
6. K. Tatemoto, and V. Mutt Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides Nature 285 1980 417 418 (Pubitemid 10047227)
7. J.M. Lundberg, K. Tatemoto, L. Terenius, P.M. Hellstrom, V. Mutt, T. Hokfelt, and B. Hamberger Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility Proc Natl Acad Sci USA 79 1982 4471 4475 (Pubitemid 12052896)
8. D. Grandt, M. Schimiczek, C. Beglinger, P. Layer, H. Goebell, V.E. Eysselein, and J.R. Reeve Jr. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36 Regul Pept 51 1994 151 159
9. R. Mentlein, P. Dahms, D. Grandt, and R. Kruger Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV Regul Pept 49 1993 133 144
10. L. Degen, S. Oesch, M. Casanova, S. Graf, S. Ketterer, J. Drewe, and C. Beglinger Effect of peptide YY3-36 on food intake in humans Gastroenterology 129 2005 1430 1436 (Pubitemid 41597385)
11. T.E. Adrian, G.L. Ferri, A.J. Bacarese-Hamilton, H.S. Fuessl, J.M. Polak, and S.R. Bloom Human distribution and release of a putative new gut hormone, peptide YY Gastroenterology 89 1985 1070 1077 (Pubitemid 16231572)
12. F. Lluis, M. Fujimura, G. Gomez, J.A. Salva, G.H. Greeley Jr. , and J.C. Thompson Cellular localization, half-life, and secretion of peptide YY Rev Esp Fisiol 45 1989 377 384 (Pubitemid 20124947)
13. P.A. Essah, J.R. Levy, S.N. Sistrun, S.M. Kelly, and J.E. Nestler Effect of macronutrient composition on postprandial peptide YY levels J Clin Endocrinol Metab 92 2007 4052 4055 (Pubitemid 47607660)
14. N. Helou, O. Obeid, S.T. Azar, and N. Hwalla Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females Ann Nutr Metab 52 2008 188 195 (Pubitemid 351990888)
15. S. Koda, Y. Date, N. Murakami, T. Shimbara, T. Hanada, K. Toshinai, A. Niijima, M. Furuya, N. Inomata, K. Osuye, and M. Nakazato The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats Endocrinology 146 2005 2369 2375 (Pubitemid 40577525)
16. A. Kanatani, S. Mashiko, N. Murai, N. Sugimoto, J. Ito, T. Fukuroda, T. Fukami, N. Morin, D.J. MacNeil, and L.H. Van der Ploeg Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice Endocrinology 141 2000 1011 1016 (Pubitemid 32260445)
17. Y. Dumont, A. Fournier, S. St-Pierre, and R. Quirion Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands J Pharmacol Exp Ther 272 1995 673 680
18. R.L. Batterham, M.A. Cowley, C.J. Small, H. Herzog, M.A. Cohen, C.L. Dakin, A.M. Wren, A.E. Brynes, M.J. Low, and M.A. Ghatei Gut hormone PYY(3-36) physiologically inhibits food intake Nature 418 2002 650 654
19. B. Sloth, J.J. Holst, A. Flint, N.T. Gregersen, and A. Astrup Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects Am J Physiol Endocrinol Metab 292 2007 E1062 E1068
20. R.L. Batterham, M.A. Cohen, S.M. Ellis, C.W. Le Roux, D.J. Withers, G.S. Frost, M.A. Ghatei, and S.R. Bloom Inhibition of food intake in obese subjects by peptide YY3-36 N Engl J Med 349 2003 941 948 (Pubitemid 37064767)
21. R.L. Batterham, D.H. ffytche, J.M. Rosenthal, F.O. Zelaya, G.J. Barker, D.J. Withers, and S.C. Williams PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans Nature 450 2007 106 109 (Pubitemid 350070563)
22. B. Sloth, L. Davidsen, J.J. Holst, A. Flint, and A. Astrup Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males Am J Physiol Endocrinol Metab 293 2007 E604 E609
23. S. Turker, E. Onur, and Y. Ozer Nasal route and drug delivery systems Pharm World Sci 26 2004 137 142 (Pubitemid 39012580)
24. I. Gantz, N. Erondu, M. Mallick, B. Musser, R. Krishna, W.K. Tanaka, K. Snyder, C. Stevens, M.A. Stroh, and H. Zhu Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults J Clin Endocrinol Metab 92 2007 1754 1757 (Pubitemid 46997183)
25. R.E. Steinert, B. Poller, M.C. Castelli, J. Drewe, and C. Beglinger Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects Am J Clin Nutr 92 2010 810 817
26. Y. Anini, X. Fu-Cheng, J.C. Cuber, A. Kervran, J. Chariot, and C. Roz Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat Pflugers Arch 438 1999 299 306 (Pubitemid 29361749)
27. B.C. Field, O.B. Chaudhri, and S.R. Bloom Bowels control brain: gut hormones and obesity Nat Rev Endocrinol 6 2010 444 453
28. N.M. Neary, C.J. Small, M.R. Druce, A.J. Park, S.M. Ellis, N.M. Semjonous, C.L. Dakin, K. Filipsson, F. Wang, and A.S. Kent Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively Endocrinology 146 2005 5120 5127 (Pubitemid 41653025)
29. B.C. Field, A.M. Wren, V. Peters, K.C. Baynes, N.M. Martin, M. Patterson, S. Alsaraf, V. Amber, K. Wynne, M.A. Ghatei, and S.R. Bloom PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans Diabetes 59 2010 1635 1639
30. N.M. Neary, B.M. McGowan, M.P. Monteiro, D.R. Jesudason, M.A. Ghatei, and S.R. Bloom No evidence of an additive inhibitory feeding effect following PP and PYY 3-36 administration Int J Obes (Lond) 32 2008 1438 1440
31. Obinepitide: 7TM Pharma. www.7TM.com; 2011.
32. N. Erondu, I. Gantz, B. Musser, S. Suryawanshi, M. Mallick, C. Addy, J. Cote, G. Bray, K. Fujioka, and H. Bays Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults Cell Metab 4 2006 275 282 (Pubitemid 44430911)
33. Shionogi Ltd SC Shionogi Announces Positive Top Line Efficacy Results from Year Long Studies of Velmeperit, A Noval NPY Y5 Receptor Antagonist being investigated for the Treatment of Obesity 2009